Recombinant Coagulation Factors and Thrombolytic Agents
Publisher
Springer New York
Reference84 articles.
1. Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899–909
2. Abshire T, Kenet G (2008) Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 14:898–902
3. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 354:716–722
4. Barnes C, Lillicrap D, Pazmino-Canizares J, Blanchette VS, Stain AM, Clark D, Hensmen C, Carcao M (2006) Pharmacokinetics of recombinant factor VIII (Kogenate-FS®) in children and causes of inter-patient pharmacokinetic variability. Haemophilia 12(Suppl 4):40–49
5. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF (1995) New variant of human tissue plasminogen activator (tPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human tPA. Circulation 92:3032–3040